235 related articles for article (PubMed ID: 31132406)
1. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.
Deshmukh V; O'Green AL; Bossard C; Seo T; Lamangan L; Ibanez M; Ghias A; Lai C; Do L; Cho S; Cahiwat J; Chiu K; Pedraza M; Anderson S; Harris R; Dellamary L; Kc S; Barroga C; Melchior B; Tam B; Kennedy S; Tambiah J; Hood J; Yazici Y
Osteoarthritis Cartilage; 2019 Sep; 27(9):1347-1360. PubMed ID: 31132406
[TBL] [Abstract][Full Text] [Related]
2. Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.
Yazici Y; McAlindon TE; Gibofsky A; Lane NE; Clauw D; Jones M; Bergfeld J; Swearingen CJ; DiFrancesco A; Simsek I; Tambiah J; Hochberg MC
Arthritis Rheumatol; 2020 Oct; 72(10):1694-1706. PubMed ID: 32432388
[TBL] [Abstract][Full Text] [Related]
3. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.
Deshmukh V; Hu H; Barroga C; Bossard C; Kc S; Dellamary L; Stewart J; Chiu K; Ibanez M; Pedraza M; Seo T; Do L; Cho S; Cahiwat J; Tam B; Tambiah JRS; Hood J; Lane NE; Yazici Y
Osteoarthritis Cartilage; 2018 Jan; 26(1):18-27. PubMed ID: 28888902
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis.
Yazici Y; McAlindon TE; Gibofsky A; Lane NE; Lattermann C; Skrepnik N; Swearingen CJ; Simsek I; Ghandehari H; DiFrancesco A; Gibbs J; Tambiah JRS; Hochberg MC
Osteoarthritis Cartilage; 2021 May; 29(5):654-666. PubMed ID: 33588087
[TBL] [Abstract][Full Text] [Related]
5. Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug.
Sabha M; Siaton BC; Hochberg MC
Expert Opin Investig Drugs; 2020 Dec; 29(12):1339-1346. PubMed ID: 33096010
[No Abstract] [Full Text] [Related]
6. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.
Yazici Y; McAlindon TE; Fleischmann R; Gibofsky A; Lane NE; Kivitz AJ; Skrepnik N; Armas E; Swearingen CJ; DiFrancesco A; Tambiah JRS; Hood J; Hochberg MC
Osteoarthritis Cartilage; 2017 Oct; 25(10):1598-1606. PubMed ID: 28711582
[TBL] [Abstract][Full Text] [Related]
7. A small-molecule inhibitor of the Wnt pathway, lorecivivint (SM04690), as a potential disease-modifying agent for the treatment of degenerative disc disease.
Deshmukh V; Ibanez M; Hu H; Cahiwat J; Wei Y; Stewart J; Hood J; Yazici Y
Spine J; 2020 Sep; 20(9):1492-1502. PubMed ID: 32413487
[TBL] [Abstract][Full Text] [Related]
8. Structure-Guided Discovery of Potent and Selective CLK2 Inhibitors for the Treatment of Knee Osteoarthritis.
Sun Y; Hu T; Zhang M; Song J; Qin Z; Liu M; Ji J; Li Z; Qiu Z; Bian J
J Med Chem; 2024 Mar; 67(6):4603-4623. PubMed ID: 38500250
[TBL] [Abstract][Full Text] [Related]
9. SM04755, a small-molecule inhibitor of the Wnt pathway, as a potential topical treatment for tendinopathy.
Deshmukh V; Seo T; O'Green AL; Ibanez M; Hofilena B; Kc S; Stewart J; Dellamary L; Chiu K; Ghias A; Barroga C; Kennedy S; Tambiah J; Hood J; Yazici Y
J Orthop Res; 2021 Sep; 39(9):2048-2061. PubMed ID: 33104243
[TBL] [Abstract][Full Text] [Related]
10. Intra-articular injection of a novel Wnt pathway inhibitor, SM04690, upregulates Wnt16 expression and reduces disease progression in temporomandibular joint osteoarthritis.
Hua B; Qiu J; Ye X; Liu X
Bone; 2022 May; 158():116372. PubMed ID: 35218985
[TBL] [Abstract][Full Text] [Related]
11. Jiawei Yanghe decoction ameliorates cartilage degradation in vitro and vivo via Wnt/β-catenin signaling pathway.
Xia H; Cao D; Yang F; Yang W; Li W; Liu P; Wang S; Yang F
Biomed Pharmacother; 2020 Feb; 122():109708. PubMed ID: 31918279
[TBL] [Abstract][Full Text] [Related]
12. The Therapeutic Effect of STAT3 Signaling-Suppressed MSC on Pain and Articular Cartilage Damage in a Rat Model of Monosodium Iodoacetate-Induced Osteoarthritis.
Lee SY; Lee SH; Na HS; Kwon JY; Kim GY; Jung K; Cho KH; Kim SA; Go EJ; Park MJ; Baek JA; Choi SY; Jhun J; Park SH; Kim SJ; Cho ML
Front Immunol; 2018; 9():2881. PubMed ID: 30619261
[TBL] [Abstract][Full Text] [Related]
13. Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial.
Tambiah JRS; Kennedy S; Swearingen CJ; Simsek I; Yazici Y; Farr J; Conaghan PG
Rheumatol Ther; 2021 Jun; 8(2):973-985. PubMed ID: 34101138
[TBL] [Abstract][Full Text] [Related]
14. Wnt signaling: a promising target for osteoarthritis therapy.
Wang Y; Fan X; Xing L; Tian F
Cell Commun Signal; 2019 Aug; 17(1):97. PubMed ID: 31420042
[TBL] [Abstract][Full Text] [Related]
15. Artemisinin Ameliorates Osteoarthritis by Inhibiting the Wnt/β-Catenin Signaling Pathway.
Zhong G; Liang R; Yao J; Li J; Jiang T; Liu J; Le Y; Shen C; Long H; Lu H; Ma S; Luo J; Miao Z; Su W; Zheng L; Zhao J
Cell Physiol Biochem; 2018; 51(6):2575-2590. PubMed ID: 30562742
[TBL] [Abstract][Full Text] [Related]
16. Effect of lorecivivint on osteoarthritis: A systematic review and meta-analysis.
Kou H; Qing Z; Zhao G; Sun X; Zhi L; Wang J; Chen X; Guo H; Zhang R; Ma J
Heliyon; 2023 Aug; 9(8):e18682. PubMed ID: 37576256
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Wnt/β-catenin signaling ameliorates osteoarthritis in a murine model of experimental osteoarthritis.
Lietman C; Wu B; Lechner S; Shinar A; Sehgal M; Rossomacha E; Datta P; Sharma A; Gandhi R; Kapoor M; Young PP
JCI Insight; 2018 Feb; 3(3):. PubMed ID: 29415892
[TBL] [Abstract][Full Text] [Related]
18. Naringenin regulates production of matrix metalloproteinases in the knee-joint and primary cultured articular chondrocytes and alleviates pain in rat osteoarthritis model.
Wang CC; Guo L; Tian FD; An N; Luo L; Hao RH; Wang B; Zhou ZH
Braz J Med Biol Res; 2017 Mar; 50(4):e5714. PubMed ID: 28355351
[TBL] [Abstract][Full Text] [Related]
19. Development of Cdc2-like Kinase 2 Inhibitors: Achievements and Future Directions.
Qin Z; Qin L; Feng X; Li Z; Bian J
J Med Chem; 2021 Sep; 64(18):13191-13211. PubMed ID: 34519506
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of the Wnt Signaling Pathway and Synovial Stem Cell Dysfunction in Osteoarthritis Development.
Huang J; Chen C; Liang C; Luo P; Xia G; Zhang L; Wang X; Wen Z; Cao X; Wu S
Stem Cells Dev; 2020 Apr; 29(7):401-413. PubMed ID: 31964233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
